James D. Marks
Advisor
Scientific Advisor
Imaginab
Japan
Biography
Dr. Marks is a Professor of Anesthesia at the University of California, San Francisco (UCSF). He is highly recognized as a pioneer in the field of antibody engineering, especially the use of antibody gene diversity libraries and display technologies to generate human therapeutic antibodies. He also has extensive experience in the biotechnology industry, having co-founded Hermes Biosciences., an early stage biotechnology company focused on the development of antibody targeted immunoliposomes for cancer therapy that was acquired by Merrimack Pharmaceuticals in 2009. Dr. Marks serves on several biopharmaceutical scientific advisory boards, has more than 180 relevant publications in the field and is an inventor on more than 100 issued or pending patents.
Research Interest
Immunology, Oncology, Pharmaceutical science
